AML patients harboring mutations in TP53, RUNX1, and DNMT3A had a high risk of disease progression and poor outcome, whereas the patients with t(15;17) and t(18;21) had a relatively favorable outcome [37]. This evidence concerns the gene DNMT3A and acute myeloid leukemia.